Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436692 | 0.87 | CCNT1 (0.44) | CCNT1CDK9KMT2ASMN1; SMN2SLC6A4 | |
| SCHEMBL3435570 | 0.84 | CCNT1 (0.38) | CCNT1CDK9KMT2ASMN1; SMN2SUV39H2 | |
| SCHEMBL3434233 | 0.82 | CDK9 (0.52) | CCNT1CDK9 | |
| SCHEMBL17672676 | 0.82 | ALK (0.42) | KMT2ASMN1; SMN2ALKSLC6A4NAMPT | |
| SCHEMBL2078054 | 0.79 | KDM4E (0.43) | CCNT1CDK9KMT2ASMN1; SMN2SUV39H2 | |
| SCHEMBL2080489 | 0.76 | PDK4 (0.52) | ALKNAMPT | |
| SCHEMBL3434596 | 0.75 | CCNT1 (0.52) | CCNT1CDK9 | |
| SCHEMBL3436192 | 0.72 | CCNT1 (0.47) | CCNT1CDK9SUV39H2HTR1A | |
| SCHEMBL520056 | 0.72 | SUV39H2 (0.53) | CCNT1CDK9KMT2ASUV39H2 | |
| SCHEMBL3567115 | 0.72 | CCNT1 (0.41) | CCNT1CDK9KMT2ASMN1; SMN2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CCNT1 3047/4885CDK9 648/4885KMT2A 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.